IRSA ASM 2024 Abstract

Objectives: To identify the rate of clinically significant post-embolisation syndrome (csPES) in our cohort of patients after uterine artery embolisation for symptomatic fibroids and to identify risk factors associated with the development of csPES.Methods: Retrospective case-control study.All patients who underwent uterine artery embolisation for symptomatic fibroids between the 18-month period of 1 March 2022 and 1 September 2023 were recruited.csPES was defined as maximum pain score on visual analogue scale of >5 out of 10, plus at least one of: morphine patient-controlled analgesia dose >10 mg, fever or use of 2 or more antiemetics.Results: Sixty-nine patients were included, mean age was 46.2 years, and median uterine volume was 393 mL (range 80-2288 mL).The rate of csPES was 47.8% (33 patients).After adjusting for confounding using multiparametric logistic regression, a positive association was seen between nulliparity and developing csPES (OR 5.51, 95% CI 1.297-23.410,P = 0.021).In addition, a trend was shown between increasing age and a reduced odds of developing csPES (OR 0.87, 95% CI 0.748-1.002,P = 0.054). Conclusion:The rate of csPES in our cohort was 47.8%, and nulliparity was strongly associated with the development of csPES.We can use this to better counsel our patients regarding the odds of csPES when these risks are present at pre-procedure consultation and target additional interventions at reducing csPES in this population.